Halozyme Therapeutics (HALO) drew fresh attention after signing a global partnership and licence agreement with Incyte to apply its Enhanze technology to subcutaneous formulations of INCA033989 for mutCALR myeloproliferative neoplasms.

Halozyme Therapeutics has also been in focus for its share price performance, with a 30 day share price return of 12.46% and a 1 year total shareholder return of 37.86% pointing to building momentum around the story, alongside longer term total shareholder returns over 3 and 5 years of 80.29% and 82.81% respectively.

If the Incyte partnership has you looking beyond a single stock, this is a good moment to scan for other healthcare focused AI opportunities using the 39 healthcare AI stocks

After Halozyme Therapeutics' recent share price move and the new Incyte agreement, the gap between the current US$77.09 price, analyst targets and intrinsic value estimates raises a simple issue: where does fair value really sit?

Most Popular Narrative: 8.1% Undervalued

Halozyme Therapeutics' most followed valuation narrative points to a fair value of $83.90 versus the last close at $77.09, putting the current share price below that reference point and raising the question of whether the recent rally has fully caught up.

The company's expanding network of global partnerships and the ramp-up of recently launched subcutaneous biologics (e.g., OCREVUS ZUNOVO, Opdivo Qvantig, Tecentriq Hybreza, RYBREVANT SC) provide a robust set of new and diversified royalty streams that are still early in their adoption curve. As these launches mature and penetration increases, especially in emerging and international markets, significant sequential revenue and EBITDA growth is anticipated.

Want to see what sits behind that fair value for Halozyme Therapeutics? The narrative is based on a specific blend of revenue growth, margin expansion and a future earnings multiple that is very different from where the stock trades today. The exact mix of those inputs might surprise you, especially the profit profile embedded several years out.

Result: Fair Value of $83.90 (UNDERVALUED)

However, this Halozyme Therapeutics narrative could still be knocked off course if patent challenges intensify or if key royalty partners see weaker demand for their therapies.

Another View: Halozyme Therapeutics Through Earnings Multiples

There is a different read on Halozyme Therapeutics when you look at the current P/E. The stock trades at 26.2x earnings, above the US Biotechs industry on 17.3x and also above a fair ratio of 19.9x, which implies less margin for error than the earlier undervalued narrative suggests.

For investors, that gap between the current P/E, peers and the fair ratio raises a simple question: is the premium a sign of confidence that the story will play out, or a risk if growth or margins land closer to the lower end of expectations, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this combination of optimism and concern around Halozyme Therapeutics leaves you undecided, consider reviewing the details for yourself using the 2 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Halozyme Therapeutics?

If Halozyme Therapeutics has sharpened your focus, do not stop here. Widening your watchlist with new, high conviction ideas can often reveal opportunities you did not expect.

• Target resilient potential by reviewing companies with stronger balance sheets and fundamentals through the solid balance sheet and fundamentals stocks screener (48 results).
• Hunt for mispriced opportunities by scanning the 45 high quality undervalued stocks where quality and valuation meet in a single shortlist.
• Uncover under-the-radar prospects before the crowd by checking the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.